Abnormal expression of homeobox genes and transthyretin in C9ORF72 expansion carriers

Objective: We performed a genome-wide brain expression study to reveal the underpinnings of diseases linked to a repeat expansion in chromosome 9 open reading frame 72 (C9ORF72). Methods: The genome-wide expression profile was investigated in brain tissue obtained from C9ORF72 expansion carriers (n = 32), patients without this expansion (n = 30), and controls (n = 20). Using quantitative real-time PCR, findings were confirmed in our entire pathologic cohort of expansion carriers (n = 56) as well as nonexpansion carriers (n = 31) and controls (n = 20). Results: Our findings were most profound in the cerebellum, where we identified 40 differentially expressed genes, when comparing expansion carriers to patients without this expansion, including 22 genes that have a homeobox (e.g., HOX genes) and/or are located within the HOX gene cluster (top hit: homeobox A5 [HOXA5]). In addition to the upregulation of multiple homeobox genes that play a vital role in neuronal development, we noticed an upregulation of transthyretin (TTR), an extracellular protein that is thought to be involved in neuroprotection. Pathway analysis aligned with these findings and revealed enrichment for gene ontology processes involved in (anatomic) development (e.g., organ morphogenesis). Additional analyses uncovered that HOXA5 and TTR levels are associated with C9ORF72 variant 2 levels as well as with intron-containing transcript levels, and thus, disease-related changes in those transcripts may have triggered the upregulation of HOXA5 and TTR. Conclusions: In conclusion, our identification of genes involved in developmental processes and neuroprotection sheds light on potential compensatory mechanisms influencing the occurrence, presentation, and/or progression of C9ORF72-related diseases.

[1]  D. Adams,et al.  Familial amyloid polyneuropathy , 2017, Current opinion in neurology.

[2]  L. Petrucelli,et al.  Novel clinical associations with specific C9ORF72 transcripts in patients with repeat expansions in C9ORF72 , 2015, Acta Neuropathologica.

[3]  Kevin F. Bieniek,et al.  Cerebellar c9RAN proteins associate with clinical and neuropathological characteristics of C9ORF72 repeat expansion carriers , 2015, Acta Neuropathologica.

[4]  Bruce L. Miller,et al.  GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport , 2015, Nature.

[5]  Sean J. Miller,et al.  The C9orf72 repeat expansion disrupts nucleocytoplasmic transport , 2015, Nature.

[6]  F. Gage,et al.  Modifiers of C9orf72 dipeptide repeat toxicity connect nucleocytoplasmic transport defects to FTD/ALS , 2015, Nature Neuroscience.

[7]  Christian A. Ross,et al.  Distinct brain transcriptome profiles in C9orf72-associated and sporadic ALS , 2015, Nature Neuroscience.

[8]  E. Kremmer,et al.  Distribution of dipeptide repeat proteins in cellular models and C9orf72 mutation cases suggests link to transcriptional silencing , 2015, Acta Neuropathologica.

[9]  G. Duester,et al.  Mechanisms of retinoic acid signalling and its roles in organ and limb development , 2015, Nature Reviews Molecular Cell Biology.

[10]  P. Wright,et al.  Mechanisms of Transthyretin Inhibition of β-Amyloid Aggregation In Vitro , 2013, The Journal of Neuroscience.

[11]  J. Rothstein,et al.  RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia , 2013, Proceedings of the National Academy of Sciences.

[12]  A. Isaacs,et al.  C9orf72 frontotemporal lobar degeneration is characterised by frequent neuronal sense and antisense RNA foci , 2013, Acta Neuropathologica.

[13]  E. Kremmer,et al.  Bidirectional transcripts of the expanded C9orf72 hexanucleotide repeat are translated into aggregating dipeptide repeat proteins , 2013, Acta Neuropathologica.

[14]  Kevin F. Bieniek,et al.  Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD/ALS , 2013, Acta Neuropathologica.

[15]  L. Petrucelli,et al.  Dipeptide repeat proteins are present in the p62 positive inclusions in patients with frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9ORF72 , 2013, Acta Neuropathologica Communications.

[16]  S. Lorenzl,et al.  Dipeptide repeat protein pathology in C9ORF72 mutation cases: clinico-pathological correlations , 2013, Acta Neuropathologica.

[17]  J. Dasen,et al.  Hox Genes: Choreographers in Neural Development, Architects of Circuit Organization , 2013, Neuron.

[18]  L. Petrucelli,et al.  Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study , 2013, The Lancet Neurology.

[19]  E. Kremmer,et al.  The C9orf72 GGGGCC Repeat Is Translated into Aggregating Dipeptide-Repeat Proteins in FTLD/ALS , 2013, Science.

[20]  Kevin F. Bieniek,et al.  Unconventional Translation of C9ORF72 GGGGCC Expansion Generates Insoluble Polypeptides Specific to c9FTD/ALS , 2013, Neuron.

[21]  Xinyi Li,et al.  Transthyretin and the brain re-visited: Is neuronal synthesis of transthyretin protective in Alzheimer's disease? , 2011, Molecular Neurodegeneration.

[22]  Bruce L. Miller,et al.  Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS , 2011, Neuron.

[23]  David Heckerman,et al.  A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD , 2011, Neuron.

[24]  E. Masliah,et al.  Neuronal Production of Transthyretin in Human and Murine Alzheimer's Disease: Is It Protective? , 2011, The Journal of Neuroscience.

[25]  A. Akinc,et al.  CSF transthyretin neuroprotection in a mouse model of brain ischemia , 2010, Journal of neurochemistry.

[26]  Merit Cudkowicz,et al.  Discovery and verification of amyotrophic lateral sclerosis biomarkers by proteomics , 2010, Muscle & nerve.

[27]  M. Pfeifle,et al.  Proteome analysis reveals candidate markers of disease progression in amyotrophic lateral sclerosis (ALS) , 2010, Neuroscience Letters.

[28]  C. E. Fleming,et al.  Transthyretin: More than meets the eye , 2009, Progress in Neurobiology.

[29]  U. Heinemann,et al.  Quantitative analysis of transthyretin, tau and amyloid-beta in patients with dementia. , 2008, Journal of Alzheimer's disease : JAD.

[30]  C. E. Fleming,et al.  Transthyretin enhances nerve regeneration , 2007, Journal of neurochemistry.

[31]  Henrik Zetterberg,et al.  Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF , 2005, Experimental Neurology.

[32]  Vanathi Gopalakrishnan,et al.  Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis , 2005, Journal of neurochemistry.

[33]  K. Blennow,et al.  Validation of a prefractionation method followed by two-dimensional electrophoresis – Applied to cerebrospinal fluid proteins from frontotemporal dementia patients , 2004, Proteome Science.